Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zuber, M.
Right arrow Articles by Rondot, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zuber, M.
Right arrow Articles by Rondot, P.
NEUROLOGY 1993;43:1715
© 1993 American Academy of Neurology

Botulinum antibodies in dystonic patients treated with type A botulinum toxin

Frequency and significance

M. Zuber, MD, M. Sebald, PhD, N. Bathien, MD, J. de Recondo, MD and P. Rondot, MD

Service de Neurologie (Drs. Zuber, Bathien, de Recondo, and Rondot), Centre R. Garcin, Hôpital Sainte-Anne and the Unité des Anaérobies (Dr. Sebald), Institut Pasteur, Paris, France.

We measured serum antibodies to botulinum toxin (ABT) in 96 patients with focal dystonia who had been treated with type A botulinum toxin. The frequency of detectable ABT was 3% (three patients). Patients with ABT had received more than 50 ng of botulinum toxin, and the shortest time between two injections was significantly less than in patients without ABT. The clinical evolution of the three patients was heterogeneous: one had decreased effectiveness with repeated injections, another had persistent improvement, and the third never responded to toxin injections.

Address correspondence and reprint requests to Dr. M. Zuber, Service de Neurologie, Centre R. Garcin, Hôpital Sainte-Anne, 1 rue Cabanis, 75674 Paris Cedex 14, France.

Received July 9,1992. Accepted for publication in final form January 28, 1993.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
S. Chen, C. Hall, and J. T. Barbieri
Substrate Recognition of VAMP-2 by Botulinum Neurotoxin B and Tetanus Neurotoxin
J. Biol. Chem., July 25, 2008; 283(30): 21153 - 21159.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Chen and J. T. Barbieri
Multiple Pocket Recognition of SNAP25 by Botulinum Neurotoxin Serotype E
J. Biol. Chem., August 31, 2007; 282(35): 25540 - 25547.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
D Dressler and F Adib Saberi
New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia
J. Neurol. Neurosurg. Psychiatry, January 1, 2007; 78(1): 108 - 109.
[Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A M O Bakheit, N V Fedorova, A A Skoromets, S L Timerbaeva, B B Bhakta, and L Coxon
The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles
J. Neurol. Neurosurg. Psychiatry, November 1, 2004; 75(11): 1558 - 1561.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
V. Wong, A. Ng, and P. Sit
Open-Label Study of Botulinum Toxin for Upper Limb Spasticity in Cerebral Palsy
J Child Neurol, February 1, 2002; 17(2): 138 - 142.
[Abstract] [PDF]

Home page
 Arch DermatolHome page
T. Karamfilov, H. Konrad, K. Karte, and U. Wollina
Lower Relapse Rate of Botulinum Toxin A Therapy for Axillary Hyperhidrosis by Dose Increase
Arch Dermatol, April 1, 2000; 136(4): 487 - 490.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
M. E. Smith and C. N. Ford
Resistance to Botulinum Toxin Injections for Spasmodic Dysphonia
Arch Otolaryngol Head Neck Surg, April 1, 2000; 126(4): 533 - 535.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. F. Brin, M. F. Lew, C. H. Adler, C. L. Comella, S. A. Factor, J. Jankovic, C. O'Brien, J. J. Murray, J. D. Wallace, A. Willmer-Hulme, et al.
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia
Neurology, October 22, 1999; 53(7): 1431 - 1431.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
P. A Hanna, J. Jankovic, and A. Vincent
Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies
J. Neurol. Neurosurg. Psychiatry, May 1, 1999; 66(5): 612 - 616.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M Naumann, K V Toyka, B M. Taleghani, J Ahmadpour, K Reiners, and H Bigalke
Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin
J. Neurol. Neurosurg. Psychiatry, December 1, 1998; 65(6): 924 - 927.
[Abstract] [Full Text]

Home page
 JAMAHome page
A. J. Stratigos, K. A. Arndt, and J. S. Dover
Advances in Cutaneous Aesthetic Surgery
JAMA, October 28, 1998; 280(16): 1397 - 1398.
[Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
B. Ford, E. D Louis, P. Greene, and S. Fahn
Outcome of selective ramisectomy for botulinum toxin resistant torticollis
J. Neurol. Neurosurg. Psychiatry, October 1, 1998; 65(4): 472 - 478.
[Abstract] [Full Text]

Home page
 J Child NeurolHome page
L. A. Koman, J. F. Mooney III, and B. P. Smith
Neuromuscular Blockade in the Management of Cerebral Palsy
J Child Neurol, November 1, 1996; 11(1_suppl): S23 - S28.
[Abstract] [PDF]

Home page
 Clin RehabilHome page
N. Jordan and M. Barnes
Botulinum toxin therapy: clinical and financial considerations
Clinical Rehabilitation, November 1, 1994; 8(4): 358 - 361.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by AAN Enterprises, Inc.